Business Wire

CIVIL-SOCIETY-20

Share
Urgent Statement by the Civil 20 to the G20 Virtual Summit on COVID-19: New Realities Require New Priorities

The following is a statement by Civil 20:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200322005022/en/

The events of this year alone, starting with the bushfires in Australia and moving to the outbreak of COVID-19, underscored the ever-growing complexity of our global shared challenges and expose the weaknesses of the current dominant economic system, and how it deepens inequalities between individuals and countries. We ask that G20 leaders recognize our new global reality and reorient this year’s G20 priorities towards building a more resilient global governance.

G20 leaders need to uphold the principles of human rights, civic engagement, and democracy. As the crisis develops, the C20 observes with great alarm the continued deterioration of the situation for many vulnerable groups in different societies. Governments must protect and extend medical care to all people without leaving anyone behind.

The infodemic surrounding the disease is equally fatal to the virus. The C20 stands in solidarity with communities suffering as a result of different governments’ lack of transparency. Governments are accountable in their response to the crisis, and work on empowering local communities and civil society actors in responding to the outbreak.

We can learn from previous public health emergencies the importance of quality care continuum, protection of human rights, anti-discrimination and isolation of people living with the diseases and affected communities. COVID-19 is a sobering reminder that we need to increase investment in what we know works: strong international partnerships, building health care delivery systems that reach everyone, research and development, and an approach to care that prioritizes the most marginalized. The C20 urges that G20 leaders consider the recommendations in the statement on pandemic preparedness released jointly with the Business 20, Labor 20, Think 20, Women 20 and Youth 20.

Another emerging lesson out of this emergency, is that hyper-globalization of our supply chains is making our trade systems extremely vulnerable to shocks. The C20 cautions G20 leaders against the ongoing attempts in trade agreement negotiations to open “health markets” to foreign investors and competition, turning health systems into yet another investment opportunity. We worry that the divide between those who can afford healthcare and those who cannot will be exacerbated.

The C20 warns that inequalities will ensue as a consequence of the outbreak. Labor policies need to be put in place to address the needs of the most vulnerable, who cannot afford to sit at home, and prepare for the expected rise in working poverty, especially in countries with a high informal economy, where women are over-represented.

The world is in need of multilateral coordination of an effective response to the economic crisis that provides adequate fiscal and monetary stimulus, while safeguarding liquidity from misuse by speculative activities. A fairly designed stimulus package should take into account not only the interest of businesses and SMEs, but also households, workers, and the most vulnerable.

A problem with multiple dimensions requires a solution by multiple actors. Members of Civil Society and humanitarian NGOs continue to face tightened financial restrictions due to risk and cost aversion by banks in complying with FATF regulations. Such financial exclusion limits our ability to respond to global emergencies.

We implore the G20 Leaders to take immediate action in responding to the substantial impact on education and the dwindling prospects of ensuring access. The world is entirely unequipped to maintain a promise of “education for all”; particularly in contexts where classrooms can no longer provide a safe environment for learning.

The C20 calls on G20 leaders to expand this year’s G20 priorities to vigilantly respond to the changes in the labor market through expanding social protection systems, ensure digital and eLearning is accessible across, prioritize child online safety, address rising risks to debt sustainability in emerging markets as they face urgent financing needs to improve health systems capacity to respond to the COVID-19 outbreak, including debt relief and attending to their exposure to volatile capital flows.

Civil Society 20 (C20) is one of the eight official Engagement Groups of the G20. It provides a platform of Civil Society Organizations around the world to bring forth a non-government and non-business voice.

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye